Newbury Pharmaceuticals AB (publ) announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in Sweden. Both products are sourced from new partners to Newbury and based on a Distribution and Marketing agreement where Newbury will perform the commercialization in the territory.